Background & Summary {#Sec1}
====================

Influenza virus has a devastating societal impact, causing up to 650,000 deaths every year worldwide^[@CR1]^. Vaccination with the seasonal mixture of strains is only partially effective, even among otherwise-healthy people, leading to serious pandemics. Vaccine efficacy is defined as the ability of a new seasonal influenza vaccine to prevent influenza-like illness compared to the placebo group, according to the US Food and Drug Administration (FDA) in their guideline for vaccine licensure^[@CR2]^. Young children and elderly, due to high susceptibility to influenza infection^[@CR3]^, are encouraged to be vaccinated annually making a placebo-controlled clinical efficacy study in this population an extremely costly and arduous undertaking. The alternative approach to correlate vaccine-mediated protection in these populations is based on immunogenicity endpoints, recommended by FDA. The appropriate immunogenicity endpoint is the influenza-specific antibody titer measured by a hemagglutination inhibition (HAI) assay to each viral strain included in the vaccine. Vaccine protection is then assessed based on seroconversion (4-fold increase in the HAI antibody titers after vaccination) and seroprotection (geometric mean HAI titer ≥40 after vaccination). The HAI titer ≥40 after vaccination is associated with a 50% reduction in risk of influenza infection or disease^[@CR4]^.

Lack of pre-existing influenza immunity, especially T cells, has been identified as one of the major predispositions for failure to generate antibody response to vaccination^[@CR5]--[@CR7]^. However, exact phenotypes of CD4^+^ and CD8^+^ T cells, which are important for protective influenza immunity in general and to vaccination with live attenuated influenza vaccine (LAIV) in specific, remain elusive. The application of computational biology and machine learning to clinical datasets holds great promise for identifying immune cell populations and genes that mediate HAI antibody responses to influenza vaccines as a correlate of vaccine protection^[@CR8]--[@CR15]^. Unfortunately the correlates of protection identified are not consistent between cohorts and study years^[@CR8],[@CR9],[@CR11],[@CR12]^. Some of the identified challenges leading to such discrepancy are small sample sizes and analysis of only one aspect of the biology, such as molecular correlates of protection by using transcriptome data^[@CR16]^. Additionally, comparison of the results of different predictive models is hampered by the lack of a consensus regarding what defines the outcome of vaccination, i.e. high vs. low responders. For these reasons, it is necessary to generate a unified dataset that includes multiple measurements across age, gender and racially diverse populations, including different vaccine types. Specifically, it is of the utmost importance to include single-cell analysis at the protein level, such as mass cytometry combined with multiple high-dimensional biological measurements, since these have power to reveal heterogeneity of the immune system^[@CR17]--[@CR21]^.

To accomplish that goal, we created FluPRINT, a dataset consisting of 13 data types in standardized tables on blood and serum samples taken from 740 individuals undergoing influenza vaccination with inactivated (IIV) or live attenuated seasonal influenza vaccines (LAIV) (Fig. [1](#Fig1){ref-type="fig"}). The FluPRINT dataset contains information on more than 3,000 parameters measured using mass cytometry (CyTOF), flow cytometry, phosphorylation-specific cytometry (phospho-flow), multiplex cytokine assays (multiplex ELISA), clinical lab tests (hormones and complete blood count), serological profiling (HAI assay) and virological tests. In the dataset, vaccine protection is measured using HAI assay, and following FDA guidelines individuals are marked as high or low responders depending on the HAI titers after vaccination. FluPRINT includes fully integrated and normalized immunology measurements from eight clinical studies conducted between 2007 to 2015 and assayed at the Human Immune Monitoring Center (HIMC) of Stanford University. Among those, one contains data from 135 donors enrolled in the 8-year long ongoing longitudinal study following immune responses to seasonal inactivated influenza vaccines. This is particularly interesting set of data that can deepen our understanding how repeated vaccination effects vaccine immunogenicity. The MySQL database containing this immense dataset is publicly available online ([www.fluprint.com](http://www.fluprint.com)). The dataset represents a unique source in terms of value and scale, which will broaden our understanding of immunogenicity of the current influenza vaccines.Fig. 1Overview of the FluPRINT dataset. The FluPRINT dataset consists of the 740 individuals from 8 clinical studies (SLVP015, SLVP017, SLVP018, SLVP021, SLVO024, SLVP028, SLVP029 and SLVP030) and 8 influenza seasons (from 2017 to 2015). (**a**) Pie chart shows distribution of donors across clinical studies. The dataset contains harmonized data from different assays, including mass and flow cytometry, phosphorylated cytometry (Phospho-flow), multiplex ELISA (Luminex assay), clinical lab tests, such as complete blood test, analysis of hormones and virological assays (CMV and EBV antibody titers) and serological profiling with hemagglutination inhibition assay, which was used to define high and low responders. (**b**) Distribution of assays across years available for each clinical study.

Methods {#Sec2}
=======

Clinical studies {#Sec3}
----------------

All studies were approved by the Stanford Institutional Review Board and performed in accordance with guidelines on human cell research. All vaccines used were licensed in the US for use in the populations studied. Peripheral blood samples were obtained at the Clinical and Translational Research Unit at Stanford University after written informed consent/assent was obtained from participants. Samples were processed and cryopreserved by the Stanford HIMC BioBank according to the standard operating protocols available online at the HIMC website (<https://iti.stanford.edu/himc/protocols.html>).

Data collection {#Sec4}
---------------

Data involving individuals enrolled in influenza vaccine studies at the Stanford-LPCH Vaccine Program was accessed from the Stanford Data Miner (SDM) which holds data processed by HIMC from 2007 up to date^[@CR22]^. The FluPRINT cohort was assembled by filtering the SDM for assays available in studies involving influenza vaccination. This resulted in a dataset containing data from 740 healthy donors enrolled in influenza vaccine studies conducted by the Stanford-LPCH Vaccine Program from 2007 to 2015 in the following studies: SLVP015, SLVP017, SLVP018, SLVP021, SLVP024, SLVP028, SLVP029 and SLVP030. Online-only Table [1](#Tab7){ref-type="table"} provides a summary of all studies including information about clinical trial identification numbers on [www.clinicaltrials.gov](http://www.clinicaltrials.gov), clinical protocols, ImmPort accession numbers to access raw data and quality reports, and finally references to published works where data was used. ImmPort is a web portal that contains data from NIAID-funded immunology studies and clinical trials (<https://immport.niaid.nih.gov/>)^[@CR23]^. All data contained in the FluPRINT dataset are made freely available through the Shared Data Portal on ImmPort repository. In all studies, except for study SLVP015, vaccine was administrated only once. The study SLVP015 was longitudinal study where 135 participants received vaccine in consecutive years from 2007--2015. In all studies, generally healthy participants were included, and in some studies (SLVP017 for the 2010, 2011 and 2013, SLVP021 and SLVP029) those that were vaccinated in the prior influenza season were excluded. A total of 121 CSV files containing processed data from various assays and studies were downloaded from SDM. The link to the 121 CSV files is provided on Zenodo^[@CR24]^. Table [1](#Tab1){ref-type="table"} provides a summary of the demographic characteristics of the FluPRINT study population. The population spans a wide age range, from a 1-year-old to a 90-year-old, with a median age of 27 years. Among 740 individuals with available experimental data, 446 were females and 294 males. The majority (491) of the individuals were Caucasian (European American ancestry). The complete demographic information is available on the Zenodo^[@CR25]^. Individuals were stratified into high and low responders, depending on their HAI antibody titers measured before and after vaccination, as described below. Figure [2](#Fig2){ref-type="fig"} shows demographic information for the FluPRINT study population, including gender, ethnicity, cytomegalovirus (CMV) status, and age stratified by the outcome to vaccination. Out of 363 individuals with measured HAI responses, 111 were identified as high responders and 252 as low responders. Overall, no major differences in the gender, ethnicity distribution, or CMV status (Fig. [2a](#Fig2){ref-type="fig"}) or age (Fig. [2b](#Fig2){ref-type="fig"}) were observed between high and low responders.Table 1Demographic characteristics for the FluPRINT study population.**Age (y)**Mean ± SD38 ± 25Median (min. to max. range)27 (1--90)**Gender**Male (%)294 (39.7%)Female (%)446 (60.3%)**Ethnicity**Caucasian (European American) (%)491 (66.35%)African American (%)13 (1.75%)American Indian and Alaska Native (%)3 (0.4%)Asian (%)86 (11.6%)Hispanic or Latino (%)5 (0.7%)Other (%)137 (18.5%)Unknown (%)5 (0.7%)Fig. 2Demographic characteristics for the FluPRINT study population stratified by the vaccination outcome. Distribution of individuals in the categories of high (red, n = 111) and low (grey, n = 252) responders regarding the (**a**) gender, ethnicity and CMV status (**b**) age distribution between high and low responders. Age is indicated in years.

Assays and data processing {#Sec5}
--------------------------

All data used were analysed and processed at the HIMC^[@CR26]^. The distribution of assays performed across clinical studies and years is illustrated in Fig. [1b](#Fig1){ref-type="fig"}. Overall, SLVP015 was the longest study, running from 2007 to 2014, spanning 135 unique individuals, while the majority of samples (249) came from the SLVP018 study (Fig. [1](#Fig1){ref-type="fig"}). Raw data, including report files, standards, controls, antibodies used are available at ImmPort (<https://immport.niaid.nih.gov/>) under identification numbers for each study provided in the Online-only Table [1](#Tab7){ref-type="table"}. Online-only Table [2](#Tab8){ref-type="table"} provides information about all assays performed, protocols, validations used and references to the published manuscripts using the data. Protocols for all assays are available online at the HIMC website (<https://iti.stanford.edu/himc/protocols.html>).

Multiplex cytokine assay {#Sec6}
------------------------

Multiplex ELISA using Luminex was performed using either polystyrene bead (for 51/52-plex) or magnetic bead kits (62/63-plex) (eBioscience/Affymetrix). The processed Luminex data available in the FluPRINT is normalized at the plate level to mitigate batch and plate effects^[@CR26]^. The two median fluorescence intensity (MFI) values for each sample for each analyte were averaged, and then log-base 2 transformed. Z-scores ((value--mean)/standard deviation) were computed, with means and standard deviations computed for each analyte for each plate. Thus, units of measurement were Zlog2 for serum Luminex. Some of the Luminex data was used in previous publications^[@CR9],[@CR10],[@CR22],[@CR27],[@CR28]^. In 2009 and 2010, for SLVP015 and SLVP018 studies, serum analytes were analysed using MSD 4- and 9-plex kits (V-PLEX Human Proinflammatory Panel II, Mesoscale, Cat No. K15053D and Human ProInflammatory 9-Plex Ultra-Sensitive Kit, Mesoscale, Cat No. K15007C) as according to the manufacturer's protocol. The assay named 'Other Luminex' was performed only for study SLVP015 in 2007 using the Human 42-Plex Polystyrene Kit (EMD Millipore, H42; MPXHCYTO060KPMX42) and data was processed in the same way as for the Luminex assays described above (measurement units reported were Zlog2)^[@CR28]^.

Hemagglutination inhibition assay {#Sec7}
---------------------------------

Serum antibody titers before vaccination and day 28 after vaccination were measured using the standard HAI assay^[@CR29]^ using strains of influenza contained in the vaccines^[@CR9],[@CR10],[@CR27]^. Geometric mean titers (GMT) were calculated for all strains of the virus contained in the vaccine, while fold change is calculated as: GMT for all vaccine strains on day 28/GMT for all vaccine strains on day 0. High responders were determined as individuals that seroconverted (4-fold or greater rise in HAI titer) and were seroprotected (GMT HAI ≥ 40).

Virological assays {#Sec8}
------------------

CMV and Epstein-Barr virus (EBV) analysis was performed using CMV IgG ELISA (Calbiotech, Cat No. CM027G) and EBV-VCA IgG ELISA (Calbiotech, Cat No. EVO10G), following manufacturer's protocols^[@CR10],[@CR27],[@CR30]^.

Immunophenotyping {#Sec9}
-----------------

Immunophenotyping was performed either with flow cytometry (Lyoplate)^[@CR27],[@CR30]^ or mass cytometry (CyTOF)^[@CR30]--[@CR32]^. Data was analysed using FlowJo software using the standard templates. Gates were adjusted on a donor-specific basis, if necessary, to control for any differences in background or positive staining intensity. The statistics was exported for each gated population to a spreadsheet. The percentage of each cell type is determined and reported as a percent of the parent cell type.

Phosphorylation-specific cytometry {#Sec10}
----------------------------------

Phospho-flow assays were performed either using flow cytometry on PBMC (for studies SLVP015, SLVP018 and SLVP021 from 2007 to 2012)^[@CR9],[@CR10],[@CR27],[@CR28],[@CR30]^ or mass cytometry on whole blood (for studies SLVP015, SLVP018 and SLVP021 in 2013)^[@CR33],[@CR34]^. The percentage of each cell type is determined and reported as a percent of the parent cell type. Median values are reported to quantitate the level of phosphorylation of each protein in response to stimulation. For phospho-flow data acquired on flow cytometer a fold change value was computed as the stimulated readout divided by the unstimulated readout (e.g. 90th percentile of MFI of CD4^+^ pSTAT5 IFNα stimulated/90th percentile of CD4^+^ pSTAT5 unstimulated cells), while for data acquired using mass cytometry a fold change was calculated by subtracting the arcsinh (intensity) between stimulated and unstimulated (arsinh stim -- arcsing unstim).

Automated importer and data harmonization {#Sec11}
-----------------------------------------

After collecting the data, a custom PHP script was generated to parse each of the 121 CSV files and to import data into the MySQL database. The source code for the script is available online at <https://github.com/LogIN-/fluprint>. The script optimizes the data harmonization process essential for combining data from different studies. Control and nonsense data were not imported, such as "CXCR3-FMO CD8+ T cells", "nonNK-nonB-nonT-nonmonocyte-nonbasophils", "viable", etc. To standardize data, the original CSV entries were cleaned into the MySQL database readable format (e.g. quotes and parenthesis replaced with underscores, "+" with text "positive", etc.). Additionally, classifications for ethnicity (Table [2](#Tab2){ref-type="table"}), vaccine names (Table [3](#Tab3){ref-type="table"}) and vaccination history (Table [4](#Tab4){ref-type="table"}) were resolved into standard forms, while assays were numerated (Table [5](#Tab5){ref-type="table"}). For example, "Fluzone single-dose syringe" and "Fluzone single-dose syringe 2009--2010" were mapped to "Fluzone" and given number 4 (Table [3](#Tab3){ref-type="table"}). In all studies, vaccines were given intramuscularly for IIV and intranasally for LAIV, except for one study where a distinct licensed formulation of IIV was given intradermally and this was labelled as Fluzone Intradermal and given number 2. During data merging, we replaced text strings with binary values. For example, for the variable of gender, female and male were replaced with zero and one. To be able to distinguish between visits in consecutive years, a unique visit identification was calculated. For the original internal visit data, each visit in one year was labelled as V1 for day zero and V2 for day seven. However, if the same individual came in the consecutive year, day zero visit would again be labelled V1, and day seven as visit V2, causing repetition of values. To avoid such repetitions in the database, we generated a unique visit ID. Therefore, for the above example, first visit in the first year would be labelled V1 for day zero and V2 for day seven, but for the next year visits would be labelled as V3 for day zero and V4 for day seven. To distinguish between Luminex assays, the prefix L50 was given to each analyte analysed with the 51/52-plex Luminex kit. Finally, we imputed new values and calculated the vaccine outcome parameter using HAI antibody titers. High responders were determined as individuals that have HAI antibody titer for all vaccine strains ≥40 after vaccination and GMT HAI fold change ≥4, following FDA guidelines for evaluation of vaccine efficacy^[@CR2]^. Vaccine outcome was expressed as a binary value: high responders were given value of one and low responders the value zero.Table 2Remapping ethnicity.OriginalRemappedCaucasian or WhiteCaucasianCaucasian or White, AsianOtherCaucasian or White, OtherOtherAsianAsianAsian, OtherOtherOtherOtherCaucasian or White, Black African American, Asian, OtherOtherCaucasian or White, Black African AmericanOtherNULLOtherNot Hispanic or LatinoOtherNon-HispanicOtherDecline to answerUnknownBlack African AmericanBlack or African AmericanBlack African American, AsianOtherCauc or White, Black Af AmOtherCaucasian or White, Pacific IslanderOtherCaucasian or White, PacIslanOtherCauc or White, Pacific IslanderOtherPacific Islander, AsianOtherAmerican Indian/Alaska native, Caucasian or WhOtherAmerican Indian/Alaska native, Caucasian or WhiteOtherAmerican Indian/Alaska native, Black African AmericanOtherAm In/Alaska native, Cauc or WOtherAm In/AlaskaNative, Black Af AmOtherAmerican Indian/Alaska nativeAmerican Indian or Alaska NativeHispanicHispanic/LatinoHispanic or LatinoHispanic/LatinoTable 3Remapping vaccine type.Vaccine receivedVaccine type IDVaccine type nameFluMist IIV4 0.2 mL intranasal spray1FlumistFluMist Intranasal spray1FlumistFluMist Intranasal Spray 2009--20101FlumistFluMist Intranasal Spray1FlumistFlumist1FlumistFluzone Intradermal-IIV32Fluzone IntradermalFluzone Intradermal2Fluzone IntradermalGSK Fluarix IIV3 single-dose syringe3FluarixFluzone 0.5 mL IIV4 SD syringe4FluzoneFluzone 0.25 mL IIV4 SD syringe5Paediatric FluzoneFluzone IIV3 multi-dose vial4FluzoneFluzone single-dose syringe4FluzoneFluzone multi-dose vial4FluzoneFluzone single-dose syringe 2009--20104FluzoneFluzone high-dose syringe6High Dose FluzoneFluzone 0.5 mL single-dose syringe4FluzoneFluzone 0.25 mL single-dose syringe5Paediatric FluzoneFluzone IIV3 High-Dose SDS6High Dose FluzoneFluzone IIV4 single-dose syringe4FluzoneFluzone High-Dose syringe6High Dose FluzoneTable 4Remapping vaccination history.OriginalRemappedNo0Yes1IIV injection/im2Doesn't know/doesn't remember/na/does not remember3LAIV4 intranasal/laiv_std_intranasal/laiv_std\_ intranasal/nasal/intranasal4Table 5Assays in the database.OriginalRemappedCMV EBV1Other immunoassay2Human Luminex 62--63 plex3CyTOF phenotyping4HAI5Human Luminex 51 plex6Phospho-flow cytokine stim (PBMC)7pCyTOF (whole blood) pheno9pCyTOF (whole blood) phospho10CBCD11Human MSD 4 plex12Lyoplate 113Human MSD 9 plex14Human Luminex 50 plex15Other Luminex16

Generating tables {#Sec12}
-----------------

To build FluPRINT database, we generated four tables, as shown in Fig. [3](#Fig3){ref-type="fig"}. Table [6](#Tab6){ref-type="table"} depicts characteristics of the FluPRINT database. In the table ***donor***, each row represents an individual given a unique encrypted identification number (study donor ID). Other fields provide information about the clinical study in which an individual was enrolled (study ID and study internal ID), gender and race. The second table, named ***donor_visits*** describes information about the donor's age, CMV and EBV status, Body Mass Index (BMI) and vaccine received on each clinical visit. Each clinical visit was given a unique identification (visit ID) in addition to the internal visit ID (provided by the clinical study) to distinguish between visits in consecutive years. For each visit, we calculated vaccine response by measuring HAI antibody response. Information about vaccine outcome is available as geometric mean titers (geo_mean), difference in the geometric mean titers before and after vaccination (delta_geo_mean), and difference for each vaccine strain (delta_single). In the last field, each individual is classified as high and low responder (vaccine_resp). On each visit, samples were analysed and information about which assays were performed (assay field) and value of the measured analytes (units and data) are stored in the ***experimental_data*** table. Finally, the ***medical_history*** table describes information connected with each clinical visit about usage of statins (statin_use) and whether an influenza vaccine was received in the past (influenza vaccine history), if yes, how many times (total_vaccines_received, self reported). Also, we provide information which type of influenza vaccine was received in the previous years (1 to 5 years prior enrolment in the clinical study). Lastly, information about influenza infection (report of MD diagnosis) history and influenza-related hospitalization (participant report) is provided.Fig. 3The FluPRINT database model. The diagram shows a schema of the FluPRINT database. Core tables, donors (red), donor_visits (yellow), experimental_data (blue) and medical_history (green) are interconnected. Tables experimental_data and medical_history are connected to the core table donor_visits. The data fields for each table are listed, including the name and the type of the data. CHAR and VARCHAR, string data as characters; INT, numeric data as integers; FLOAT, approximate numeric data values; DECIMAL, exact numeric data values; DATETIME, temporal data values; TINYINT, numeric data as integers (range 0--255); BOOLEAN, numeric data with Boolean values (zero/one). Maximal number of characters allowed in the data fields is denoted as number in parenthesis.Table 6The characteristics of the FluPRINT database.Table nameRowsColumnsDescription*donors*7406Each row in this table is one donor. Donor is described with 5 additional parameters that include unique identification (*donor_id* and *study_donor_id*), identification for the study (*study_id*), full internal name of the study (*study_internal_id*), gender and race.*donor_visits*2,93718Each row represents a donor at the particular visit (*visit_id*). Additionally, information about internal visit identification (*visit_internal_id*), date of the visit (*visit_year* and *visit_day*), pre- or post-vaccination visit for HAI assay (*visit_type_hai*), age at the visit (*age* and *age_round*), CMV/EBV status, BMI index at the visit are provided. Additionally, type of vaccine received (*vaccine*) and other calculated measures for HAI assay (*geo_mean*, *d_geo_mean*, *d_single*, *vaccine_resp*) are provided.*experimental_data*371,2609Each row represents a donor at particular visit (*donor_visits_id*). At each visit, assay that was performed is listed (*assay)* along with the names and values for measured analytes (*name*, *name_formatted*, *subset*, *units* and *data*).*Medical_history*74018Each row is one donor at first visit described by 15 additional parameters. These include usage of statins (*statin_use*) and history of receiving influenza vaccines (*flu_vaccination_history*). If donor received vaccination before enrollment, the survey information is provided about how many vaccines were received (*total_vaccines_received*), and the type of vaccines for each prior season (fields for the one year before enrolment: *vaccinated_1yr_prior* and *vaccine_type_1yr_prior*). This information is provided for up to 5 years prior enrolment in the clinical study and is by report, not record verified.

Data Records {#Sec13}
============

The FluPRINT dataset described herein is available online for use by the research community and can be downloaded directly from a research data repository Zenodo^[@CR35]^. Additionally, the dataset can be imported in the MySQL database for further manipulation and data extraction. The instructions how to import FluPRINT into the database are available at github (<https://github.com/LogIN-/fluprint>). The summary of the dataset, including the number of observations, fields and description for each table is provided in Table [6](#Tab6){ref-type="table"}.

Technical Validation {#Sec14}
====================

The objective of the current study was to ensure that the FluPRINT dataset accurately reflects processed data available in SDM. Technical data validation was carried in previous published studies referred in the Online-only Table [2](#Tab8){ref-type="table"}. Data was downloaded from the original source, and here we focused on ensuring that data records were accurately harmonized, merged and mapped in the unifying FluPRINT database.

The FluPRINT dataset was validated on two levels: (1) upon insertion and (2) after the data was inserted into the database. To validate data on insertion, we created loggers to monitor import of the CSV files into the database. This ensured easier and more effective troubleshooting of potential problems and contributed to the monitoring of the import process. Two different sets were used: (1) informative and (2) error loggers. Informative loggers provided information about which processing step has started or finished and how many samples have been processed in that particular step. This allowed us to monitor that correct number of samples was processed. Error loggers provided exact identification and name of the data which could not be imported into the database, usually caused by missing or incorrect user input, such as "... assay is missing. Skipping ... '\$row'". This facilitated the process to identify erroneous data, which were then manually reviewed, corrected, and updated.

Once the database was built, a manual review of data was performed to ensure accuracy and integrity of the dataset. Several random individuals were chosen and the accuracy of data was evaluated by comparison with the raw data. Additionally, we evaluated total number of all donors, assays performed, clinical studies and years with the raw data available at the SDM.

Usage Notes {#Sec15}
===========

Recent advances in the computational biology and the development of novel machine learning algorithms, especially deep learning, make it possible to extract knowledge and identify patterns in an unbiased manner from large clinical datasets. Application of machine learning algorithms to clinical datasets can reveal biomarkers for different diseases, therapies^[@CR36]^, including vaccinations^[@CR8],[@CR9],[@CR12]^. The data from the FluPRINT study can be used to identify cellular and molecular baseline biomarkers that govern successful antibody response to influenza vaccines (IIV and LAIV) across different influenza seasons and a broad age population. The HAI antibody response to influenza vaccines is considered as an alternative way to compare immunogenicity of the vaccines in susceptible groups where placebo-controlled clinical efficacy study cannot be performed. Since FluPRINT dataset is provided as a database, this facilitates further analysis. Queries can be easily performed to obtain a single CSV file. For example, researchers interested in understanding which immune cells and chemokines can differentiate between high and low responders that received inactivated influenza vaccine could search the FluPRINT database. In the database, they can find all donors for which flow cytometry or mass cytometry were performed together with Luminex assays, for which donors the HAI response was measured, and all the donors who received inactivated influenza vaccine. The resulting CSV file can then easily be used for downstream analysis.

Major advantages of this dataset are the mapping of the vaccine outcome, classifying individuals as high or low responders, standardization of the data from different clinical studies, and from different assays. This data harmonization process allows for direct comparison of immune cell frequency, phenotype, and functionality and quantity of chemokines and cytokines shared between individuals before or after influenza vaccinations. By releasing the FluPRINT database and the source code, we provide users with the ability to continue building upon this resource and to update the database with their data and other databases.

Online-only Tables {#Sec16}
==================

Online-only Table 1Characteristics of the clinical studies included in the FluPRINT dataset.Stanford study IDClinicalTrials.gov IDNameDescriptionVaccinesData in FluPRINTImmPort ID\
([www.immport.org](http://www.immport.org))Ref.SLVP015NCT01827462Comparison of immune responses to influenza vaccine in adults of different ages (2007--2017)**Who**: 18--100yo healthy participants**How**: immunized annually with the seasonal inactivated influenza vaccines from 2007--2017**When**: Blood samples acquired before immunization (Day 0), on days 6--8 and 28 after immunization**2007--2013**Seasonal trivalent, inactivated influenza vaccines (Fluzone)**2014--2015**High Dose trivalent Fluzone for participants ≥ 65yo and quadrivalent Fluzone for younger participants**135 donors**Assays:51-plex Luminex62-plex LuminexMSD 4plexMSD9plexOther LuminexHAICMV/EBVHormonesCyTOF phenotypeLyoplatePhospho Cytof phenoPhospho cytof phosphoPhosphoflowCBCDSDY887 (2007)SDY212 (2008)SDY312 (2009)SDY311 (2010)SDY112 (2011)SDY315 (2012)SDY478 (2013)SDY1464 (2014)^[@CR8]--\ [@CR10],\ [@CR28],\ [@CR37]--\ [@CR46]^SLVP017NCT02133781NCT03020498NCT03020537B-cell immunity to influenza(2009--2011 and 2013)**Who:**1--2yo (2013), 8--100yo healthy participants who did not receive the seasonal influenza vaccine in previous years (2010, 2011 and 2013)**How:** immunized with either seasonal inactivated or live, attenuated influenza vaccines in 2009, 2010, 2011 and 2013**When:** Blood samples acquired before immunization (Day 0) and on day 28 after immunization**2009--2011**Seasonal trivalent, inactivated influenza vaccines (Fluzone) or seasonal live, attenuated influenza vaccine (FluMist)**2013**Seasonal trivalent inactivated influenza vaccine- (Fluzone) - pediatric formulation for 1--2yo children**153 donors**Assays:51-plex Luminex62-plex LuminexHAICMV/EBVCyTOF phenotypeCBCDSDY1467(2009)SDY1468(2010)SDY1469(2011)SDY1470(2012)SDY1471(2013)^[@CR27],\ [@CR47]--\ [@CR50]^SLVP018NCT01987349NCT03022396NCT03022422NCT03022435NCT03023176T-cell and general immune response to seasonal influenza vaccine(2009--2013)**Who:** 1--8yo (2013), 8--100yo healthy participants**How:** immunized with either seasonal inactivated or live, attenuated influenza vaccines from 2009--2013**When:** Blood samples acquired before immunization (Day 0), days 7--10 and 28 after immunization**2009--2010**Seasonal trivalent inactivated influenza vaccine (Fluzone) or seasonal trivalent live attenuated influenza vaccine (FluMist)**2010**High Dose trivalent Fluzone for participants ≥ 65yo**2013**Seasonal trivalent, inactivated influenza Pediatric Dose (Fluzone, 0.25 ml) for 1--3yo children**249 donors**Assays:51-plex Luminex62-plex LuminexMSD 4plexMSD 9plexHAICMV/EBVHormonesCyTOF phenotypeLyoplatePhospho Cytof phenoPhospho cytof phosphoPhosphoflowCBCDSDY514(2009)SDY515(2010)SDY519(2011)SDY1465(2012)SDY1466(2013)^[@CR27],\ [@CR44],\ [@CR51]--\ [@CR57]^SLVP021NCT02141581Plasmablast trafficking and antibody response in influenza vaccination (2011--2014)**Who:** 8--34yo healthy participants who did not receive the seasonal influenza vaccine in previous years**How:** immunized with either seasonal inactivated influenza vaccines, given intramuscularly or intradermally, or live, attenuated influenza vaccines from 2011--2014**When:** Blood samples acquired before immunization (Day 0), days 6--8 and 24--32 after immunization**2011--2014**Seasonal trivalent inactivated influenza vaccine (Fluzone) given either intramuscularly or intradermally**2011--2012**Seasonal trivalent live attenuated influenza vaccine (FluMist)**84 donors**Assays:51-plex Luminex62-plex LuminexHAICMV/EBVHormonesCyTOF phenotypePhospho Cytof phenoPhospho cytof phosphoPhosphoflowCBCDSDY113 (2011)SDY305 (2012)SDY472 (2013)SDY1479 (2014)^[@CR58]--\ [@CR60]^SLVP024NCT03023683Protective mechanisms against a pandemic respiratory virus (2012)**Who:** 2--49yo healthy participants**How:** immunized with the seasonal live, attenuated influenza vaccine**When:** Blood samples only from 18--42yo adults acquired before immunization (Day 0), days 7 and 28 after immunizationSeasonal live, attenuated influenza vaccine (FluMist)**Donors: 8**Assays:HAIPhosphoflowSDY1472SLVP028NCT03088904Genetic and environmental factors in the response to influenza vaccination(2014--2018)**Who:** 12--49yo healthy participants**How:** immunized with either seasonal inactivated or live, attenuated influenza vaccines from 2014--2018**When:** Blood samples acquired before immunization (Day 0), days 6--8 and 28 + 7 after immunizationSeasonal quadrivalent inactivated influenza vaccine (Fluzone) or seasonal quadrivalent live attenuated influenza vaccine (FluMist)**Donors: 52**Assays:62-plex LuminexHAICMV/EBVHormonesCyTOF phenotypeSDY1480 (2014)SDY1481 (2015)SLVP029NCT03028974Innate and acquired immunity to influenza infection and immunization(2014--2017)**Who:** 6 mo-49yo healthy participants(who did not receive LAIV in the prior season nor received influenza immunizations in two or more prior seasons)**How:** immunized with either seasonal inactivated or live, attenuated influenza vaccines from 2014--2017**When:** Blood samples acquired before immunization (Day 0), days 7 and 28 after immunization. Children \<9 yrs received 2 immunizations with the second blood samples acquired 28 days after second immunizationSeasonal quadrivalent inactivated influenza vaccine (Fluzone) or seasonal quadrivalent live attenuated influenza vaccine (FluMist)**Donors: 47**Assays:62-plex LuminexHAICMV/EBVHormonesCyTOF phenotypeSDY1482 (2014)SDY1483 (2015)SLVP030NCT03453801The role of CD4+ memory phenotype, memory, and effector t cells in vaccination and infection(2014--2019)**Who:** 6 mo-10yo healthy participants**How:** immunized annually with either seasonal inactivated or live, attenuated influenza vaccines from 2014--2019**When:** Blood samples acquired before immunization (Day 0), days 7 and 60 after immunization. Children with no prior influenza vaccine received 2 immunizations with the second blood sample acquired 60 days after second immunizationSeasonal quadrivalent inactivated influenza vaccine (Fluzone) or seasonal quadrivalent live attenuated influenza vaccine (FluMist)Seasonal trivalent, inactivated influenza Pediatric Dose (Fluzone, 0.25 ml) for 6--35mo children**Donors: 12**Assays:62-plex LuminexHAICMV/EBVHormonesCyTOF phenotypeSDY1484 (2014)

Online-only Table 2Assays performed.AssaysProtocolsValidationsRef.51/52-plex LuminexHIMC website:"Luminex-Polystyrene bead kits/Luminex"Report file available at ImmPort (<https://immport.niaid.nih.gov/>) contains all information of standards, Curve fitting, Bead counts to examine quality of assay and CV of both samples and standards.^[@CR9],\ [@CR10],\ [@CR22],\ [@CR27],\ [@CR28]^62/63-plex LuminexHIMC website"Luminex -- eBioscience/Affymetrix Magnetic bead Kits"MSD 4-plexV-PLEX Human Proinflammatory Panel II (Mesoscale, Cat No K15053D)Manufacturer standards^[@CR22]^MSD 9-plexHuman ProInflammatory 9-Plex Ultra-Sensitive Kit (Mesoscale, Cat No K15007C)Other LuminexHuman 42-Plex Polystyrene Kit(EMD Millipore, H42; MPXHCYTO060KPMX42)Report file available at ImmPort (<https://immport.niaid.nih.gov/>) contains all information of standards, Curve fitting, Bead counts to examine quality of assay and CV of both samples and standards.^[@CR28]^HAIHIMC website"Hemagglutinin inhibition (HAI) assay"Sample, virus control, HIMC human control serum (CONS2) and control PBS available at ImmPort.^[@CR9],\ [@CR10],\ [@CR27]^CMV/EBVCMV IgG ELISA (Calbiotech, Cat No CM027G)EBV-VCA IgG ELISA (Calbiotech, Cat No EVO10G)Manufacturer standards^[@CR10],\ [@CR27],\ [@CR30]^HormonesFree Testosterone ELISA Kit (Calbiotech) andCustom Steroid Hormone Panel (human) Assay Kit (Mesosclae, MSD 4-plex)Manufacturer standards^[@CR8]^CyTOF phenotypeHIMC website"CyTOF Immunophenotyping/CyTOF phenotyping"Data analysed using FlowJo software. Gates were adjusted on a donor-specific basis. The statistics for each gated population was exported to an Excel spreadsheet. The percentage of each cell type is determined and reported as a percent of the parent cell type.^[@CR27],\ [@CR30]^Protocols^[@CR31],[@CR32]^LyoplateHIMC website:"Flow cytometry phenotyping"^[@CR27],\ [@CR30]^Phospho-CyTOF(whole blood)HIMC website"Whole blood phospho-CyTOF/Phosphoflow whole blood CYTOF"The percentage of each cell type was determined and reported as a percent of the parent cell type. Median values were reported to quantitate the level of phosphorylation of each protein in response to stimulation.Protocol^[@CR34]^Phospho-flowHIMC website"Phospho-flow-cytokine/Phosphoepitope Flow Cytometry (Cytokine stimulation, pSTAT readouts)"^[@CR9],\ [@CR10],\ [@CR27],\ [@CR28],\ [@CR30]^Blood count(CBCD)Clinical haematology test performed on a Coulter counterPerformed at the Stanford Clinical Lab---
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